On the Tip of Our Tongue: Sublingual Cyclobenzaprine and Fibromyalgia

Authors: Malvika Lall, MD, Christopher D. Jackson, MD


Fibromyalgia (FM) is a complex disease that affects 2% of the US population.1 The etiology and pathophysiology of FM are largely unknown2,3; however, genetic factors, infections, and physical or emotional events are known aggravating factors. Patients with FM typically report muscle pain and tenderness, most commonly in the upper mid-trapezius muscle, the lateral epicondyle, the second costochondral junction, and the greater trochanter. The current diagnostic criteria for FM include 3 months of widespread multisite pain and tenderness without clinical or laboratory evidence of systemic inflammation.
Posted in: Rheumatology and Orthopedics24

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547–1555.
2. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19–28.
3. Goldenberg DL. Fibromyalgia syndrome. An emerging but controversial condition. JAMA 1987;257:2782–2787.
4. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600–610.
5. Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 revisions to the 2010/ 2011fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–329.
6. Falco P, Galosi E, Di Stefano G, et al. Autonomic small-fiber pathology in patients with fibromyalgia. J Pain 2023 [publish ahead of print], DOI: 10. 1016/j.jpain.2023.07.020.
7. D’Onghia M, Ciaffi J, Ruscitti P, et al. The economic burden of fibromyalgia: a systematic literature review. Semin Arthritis Rheum 2022;56:152060.
8. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318–328.
9. Winslow BT, Vandal C, Dang L. Fibromyalgia: diagnosis and management. Am Fam Physician 2023;107:137–144.
10. Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004;51:9–13.
11. Lederman S, Arnold LM, Vaughn B, et al. Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2023 [publish ahead of print], DOI: 10.1002/acr.25142.
12. Sullivan G, Kiu R, Stillwell H, et al. Steady-state pharmacokinetic properties of a sublingual formulation of cyclobenzaprine (CBP) HCl(TNX-102 SL*): comparison to simulations of oral immediate release CBP. Poster presented at: 59th Annual Meeting of the American Society of Clinical Psychopharmacology; May 28–31, 2019; Scottsdale, AZ.
13. Daugherty B, Gershell L, Lederman S. Cyclobenzaprine (CBP) and its major metabolite norcyclobenzaprine (nCBP) are potent antagonists of human serotonin receptor 2a (5HT2a), histamine receptor H-1and alpha-adrenergic receptors: mechanistic and safety implications for treating fibromyalgia syndrome by improving sleep quality [abstract no. 960]. Paper presented at: the American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting; November 9–14, 2012; Washington, DC.
14. Lederman S, Gendreau M, Clauw DJ, et al. Bedtime, rapidly absorbed sublingual cyclobenzaprine (TNX-102 SL) for the treatment of fibromyalgia: results of a phase 2b randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol 2015;67(Suppl 10). Accessed January 30, 2024.
15. Sullivan G, Gendreau RM, Gendreau J, et al. A phase 3 randomized, double-blind, placebo-controlled trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) for the treatment of fibromyalgia (FM): evidence for a broad spectrum of activity on the FM syndrome [abstract]. Arthritis Rheumatol 2019; 71(Suppl 10). Accessed December 2, 2023.